Clinical Trial

A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This clinical research study is to learn about the safety of the NovoTTF-200M and Novo TTF-200A Systems, when used either alone or in combination with standard therapy, in patients with tumors that did not respond to treatment.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-03-26; most recent amendment 2026-04-15.
Status change: Not Yet Recruiting → Recruiting 2025-10-09
Trial Details
NCT Number NCT06906900
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: NovoCure Ltd.
Conditions Spinal Metastasis
Enrollment 30 participants
Start Date 2025-08-18
Primary Completion 2027-02-17 (estimated)
Study Completion 2029-02-17 (estimated)
Updated on ClinicalTrials.gov 2026-04-20